Alnylam Pharmaceuticals Inc (ALNY)
246.80
-1.99
(-0.80%)
USD |
NASDAQ |
Nov 21, 16:00
249.68
+2.88
(+1.17%)
After-Hours: 20:00
Alnylam Pharmaceuticals Revenue (Quarterly): 500.92M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 500.92M |
| June 30, 2024 | 659.82M |
| March 31, 2024 | 494.33M |
| December 31, 2023 | 439.72M |
| September 30, 2023 | 750.53M |
| June 30, 2023 | 318.75M |
| March 31, 2023 | 319.29M |
| December 31, 2022 | 335.04M |
| September 30, 2022 | 264.31M |
| June 30, 2022 | 224.82M |
| March 31, 2022 | 213.26M |
| December 31, 2021 | 258.54M |
| September 30, 2021 | 187.63M |
| June 30, 2021 | 220.55M |
| March 31, 2021 | 177.57M |
| December 31, 2020 | 163.56M |
| September 30, 2020 | 125.85M |
| June 30, 2020 | 103.96M |
| March 31, 2020 | 99.48M |
| December 31, 2019 | 71.68M |
| September 30, 2019 | 70.06M |
| June 30, 2019 | 44.71M |
| March 31, 2019 | 33.29M |
| December 31, 2018 | 21.03M |
| September 30, 2018 | 2.069M |
| Date | Value |
|---|---|
| June 30, 2018 | 29.91M |
| March 31, 2018 | 21.90M |
| December 31, 2017 | 37.92M |
| September 30, 2017 | 17.10M |
| June 30, 2017 | 15.93M |
| March 31, 2017 | 18.96M |
| December 31, 2016 | 17.45M |
| September 30, 2016 | 13.65M |
| June 30, 2016 | 8.709M |
| March 31, 2016 | 7.345M |
| December 31, 2015 | 7.551M |
| September 30, 2015 | 6.324M |
| June 30, 2015 | 8.685M |
| March 31, 2015 | 18.54M |
| December 31, 2014 | 24.02M |
| September 30, 2014 | 10.97M |
| June 30, 2014 | 7.295M |
| March 31, 2014 | 8.275M |
| December 31, 2013 | 10.85M |
| September 30, 2013 | 8.991M |
| June 30, 2013 | 8.687M |
| March 31, 2013 | 18.64M |
| December 31, 2012 | 8.495M |
| September 30, 2012 | 16.76M |
| June 30, 2012 | 20.88M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
71.68M
Minimum
Dec 2019
750.53M
Maximum
Sep 2023
296.48M
Average
241.68M
Median
Revenue (Quarterly) Benchmarks
| Pfizer Inc | 17.70B |
| BridgeBio Pharma Inc | 2.732M |
| Gilead Sciences Inc | 7.545B |
| Johnson & Johnson | 22.47B |
| Regeneron Pharmaceuticals Inc | 3.721B |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -111.57M |
| Total Expenses (Quarterly) | 577.82M |
| EPS Diluted (Quarterly) | -0.87 |
| Enterprise Value | 30.08B |
| Gross Profit Margin (Quarterly) | 82.85% |
| Profit Margin (Quarterly) | -22.27% |
| Earnings Yield | -1.06% |
| Normalized Earnings Yield | -0.7449 |